S H Kelkar and Company Limited (SHK) Earnings Call Transcript
November 3, 2026
Earnings Call Speaker Segments
Good day, everyone, and welcome to the SH Kelkar & Company Limited earnings conference call. <<operator_script>> At this point, I'll turn the conference over to Mr. Anoop Poojari of CDR India. Thank you, and the floor is yours, Mr. Poojari.
Thanks a lot. Good afternoon, everyone, and thanks for being with us on the Q2 and H1 FY 2027 Earnings Conference Call of SH Kelkar & Company Limited. Joining us today are Mr. Kedar Vaze, Whole-Time Director and Group CEO; Mr. B. Ramakrishnan, CEO, Fragrances, Asia and U.S.A.; and Mr. Jagdish Agarwal, Group Chief Financial Officer of the company. We'll start with opening remarks from the management, and after that we'll open the forum for a question-and-answer session. Before we begin, I want to note that certain statements on today's call could be forward-looking in nature, and a disclaimer to that effect is included in the earnings presentation that was shared with you earlier. I'd now like to invite Kedar to give his opening remarks.
Good afternoon, everyone, and thanks for being with us on the SH Kelkar & Company earnings call covering the second quarter and first half of financial year 2027. We've had an encouraging first half, with solid momentum across our businesses. In Fragrance, revenue rose 11.9% during the first half of '27, supported by India and international markets. If you set aside the low-margin business we divested in quarter 4 '26, which had annual revenue of roughly INR 50 crores, underlying growth came in at about 14%. Our priorities stay the same: leverage our creative and technical expertise, respond to evolving customer requirements, and strengthen our presence across key markets, particularly the new investment areas in Europe and America. Flavour continued to do well, posting strong growth of 47% in the first half. This business has gained from demand across domestic and international markets. We still see significant long-term potential in this segment and remain focused on growing our contribution to it through innovation and continued development at application centers. As you know, over the past few years we have invested substantially in building global creative, technical, and manufacturing capabilities across developed markets in Europe and America.
Our priority at this point is to lock in those gains and use them to drive sustained growth by launching new products more quickly. As we look forward, although the external environment will probably stay dynamic, our strategic direction has not changed. We are still concentrated on strengthening our standing as a technology-driven Fragrance and Flavour business that competes globally, so that we can draw on our innovation capabilities, scientific expertise, and integrated global platform to produce sustainable, profitable growth over the long term. Ongoing work on proprietary molecules, formulation technologies, and sustainable ingredients is set to be our main point of differentiation as we expand with confidence into the new geographies we are entering. With that said, I will pass things to Jagdish so he can walk you through the financial performance in more detail. Jagdish, over to you.
Thanks, Kedar. Good afternoon, everyone, and I appreciate you being with us. I'll walk you through how we performed financially in the second quarter and the first half of FY '27. Consolidated revenue from operations rose 15% Y-o-Y to INR 636 crores in Q2 of FY '27, which brought H1 revenue to INR 1,299 crores, up 14%. First-half EBITDA climbed 33% to INR 168 crores, and EBITDA margins improved to 13%. On a consolidated basis, gross margins stayed broadly stable across the first half of FY '27 despite volatility in raw material prices and global sourcing conditions. Keeping profitability protected remained a key priority, and we were supported by proactive raw material planning, appropriate pricing actions, operational efficiencies and continued cost optimization. Those measures have helped us handle input cost pressures and sustain operating performance in a challenging environment. In the Fragrance segment, H1 revenue rose 11.9% Y-o-Y to INR 1,088 crores. Growth was broad-based across geographies. The Flavour segment kept up its strong growth trajectory, with H1 revenue up 47% on a Y-o-Y basis to INR 184 crores. Flavour's performance was backed by sustained demand and deeper customer engagement across domestic and international markets.
A larger revenue base likewise played a part in boosting segment profitability. Although we continue to feel good about how this business is performing, growth may not proceed at an even rate from quarter to quarter, since customer order timing affects it. Turning to the balance sheet: net debt was INR 911 crores on September 30, 2026. Through the first half, we kept inventory at elevated levels at all times so that supply would stay continuous and customer commitments could be met despite uncertainty in global sourcing and raw material availability. That raised working capital. We anticipate that the debt level in September will prove to be the peak for this year, with a decrease expected by March 2027 as we bring inventory levels down. For the current financial year, our aim is to steadily enhance cash generation and lower debt year on year, which will reinforce our balance sheet and increase financial flexibility. Going forward, we will stay focused on maintaining operating performance, safeguarding profitability and raising working capital efficiency. We think these priorities will underpin ongoing business growth while fortifying our financial position over the long term. With that, I would ask the moderator to open the floor for questions.
<<operator_script>> Thanks. Our first question is from Abhijit Akella at KIT.
To start with, could you give us an update on the big CapEx projects — the new ones currently underway, both in India and overseas? What are the timelines on those? And also, how do you expect the ramp-up to go?
The CapEx in Europe is basically finished. So that factory has been in use since May. During the second quarter, we saw it running at full capacity. As for the CapEx projects in India, especially the Fragrance factory renewal, we expect completion by the end of this year, with it coming into use in quarter 4. Then, in the following year, we'll move the factories out of Mulund into the new facility. A second factory is also anticipated in financial year '27, '28. Additional CapEx will be factored in. After that, the second Mulund factory will shift over to the second plant in <<inaudible>> Vashivali. That's likely to take place. So the first factory comes into use in quarter 4 this year, and the second one comes into use in quarter 4 next year, which would wrap up our major CapEx expansion as we satisfy our domestic needs for Fragrance and Flavour growth over the coming few decades.
Also, there was another point—those overseas development centers we've established in 3 markets. Is there anything new on how that's going, particularly regarding conversations with customers? Are you seeing any momentum when it comes to project inflows?
For the first half, we've completed budgeted sales in the U.S. So in the U.S. market, we've already begun generating revenues. The numbers are small. Ramping up will take a couple of years, and there is active momentum. We also have our first sales in Germany and our first sales in the U.K. market. So we are on track to begin to monetize our investments, which we have concluded in the last two years.
Understood. My final question concerns the demand picture by region. Could you describe how customer demand appears at present, along with your capacity to pass through any input cost pressures you might be encountering?
At this point, I feel fairly optimistic that supply chain problems and what we might call the Middle East oil crisis will ease or at least settle down, depending on the U.S. midterm elections and their net effect. Our paradigm assumes some cost stabilization, followed by fast growth throughout Asia and ongoing expansion in European markets. So we anticipate markets rebounding, with very strong demand in the second half of the year. The ongoing Middle East situation, I think, is the biggest risk factor here. And in a few days, when the U.S. midterm election results come in and any net changes or shifts in policy take place, we expect to understand better where that is headed. But we are very hopeful and very optimistic that raw material prices will stabilize and demand will be rapid. We don't expect any subdued markets. During the first half of the year, the Middle East market has been low-key. We have kept growing, but at lower growth rates than we experienced in previous years. So I expect growth rates probably to resume at a better rate in the second half as well.
Bharat Gupta from Fair Value Capital has the next question.
Hopefully you can hear me clearly. There are a couple of things I'd like to ask about. The first concerns demand here at home. You said it has held up well. Yet when we look at the figures, growth on the domestic Fragrance side has come in at about 9%. Could you break that growth down between volume and the value addition side overall — how does that split work?
Cost growth came in at roughly 5%, while volume growth was 4%.
Right. And when we look at the commentary that FMCG companies have been sharing, they've reported double-digit growth across this space. So how do we see growth splitting when it comes to our Tier 1, Tier 2, and Tier 3 clients, where we've managed to gain market share?
No, I think when you look at the growth we reported and how it came about, we've also been seeing fast expansion among big clients. Growth has been smaller with the smaller clients. So with inflation running higher, as is typical, larger brands and larger companies are in a better position to pass along that kind of cost, and they hold the inventory and the contracts. So we've witnessed this repeatedly during periods of inflation and higher pricing — bigger brands pick up some volume share. But that's very short-lived. So we expect that once market pricing settles, we'll get back to growth in the mid and smaller sector.
Basically, the moderate growth we’re seeing across the domestic space has mostly come from — you could say — somewhat muted performance among the small and Tier 2 clients.
We're also aware that we deliberately stepped away from low-margin categories amounting to roughly INR 25 crores of revenue. So in that sense, this isn't like-for-like growth. The like-for-like figure comes in closer to 12%.
And then just going back to the RFQ side for a second. Could you give us an update on how the RFQs that are under evaluation right now are progressing? And have there been any meaningful developments when it comes to new customer wins, conversions, or any incremental wallet share opportunity?
We don't have any particular RFQs we're taking part in. This is a continuous one-on-one interaction with a large number of clients. We keep working with clients across every market, both bigger clients and midsized clients, growing our share of wallet with existing clients and bringing in new clients too. So it's a continuous process. We serve more than 5,000 clients around the world, and we're adding new clients along with new product wallet share among the clients we already have.
One more thing—regarding the spending that's been circulating on the CDC side, what type of expenditure should we expect for this fiscal year and also for the next one?
Our hiring is finished, and every CDC in Germany, Manchester, and the U.S. is now up and running. So the first half, in a sense, reflects the full cost base. Naturally, a few people at the margins will join or leave as circumstances change. That said, no further investment is going into any center. Every center has its staff, and all of them are operational. As I said, Germany, the U.K., and the U.S.A. each have their first sales recorded. So everything is now moving forward.
Turning to margins, Flavours has kept performing consistently well. Demand has improved strongly, and that shows in the margins too. So do you see that level of margin as sustainable? And will their margins improve further as well, given that CDC spending is set to moderate over the coming quarters?
On the gross margin side, nothing dramatically different is expected from us. The market continues to show some inflation and availability challenges. Should conditions loosen — and, as I said, we're monitoring geopolitical developments closely and will adjust our plans — then we could likely capture roughly a 0.5% gain in the margin profile. If not, gross margins should land around 43%. Regarding the EBITDA level, as sales grow, operating leverage comes into play, since our fixed costs at the CDCs are largely already established. With growth, that operating leverage will begin to show beneath the gross margin line when it comes to EBITDA percentage.
And since RM pricing is running higher and inflationary headwinds are still with us. So on the subject of bringing net debt down, do we remain committed to the goal of staying under the FY '26 levels? Or might inventory rise somewhat given the geopolitical situation?
No — inventory is already elevated because of the situation we're in. So we're not anticipating it going up any more. As a matter of fact, our plan for the quarters ahead is to bring down how inventory-intensive the business is, along with its working capital intensity.
Riddhesh Gandhi from Discovery Capital has the next question.
Starting in 2019—excluding 2021, a COVID year—our ROCE has stayed below 12% every year. I get that we're putting a fair amount of growth into CapEx, and once that capacity is utilized, the return should rise. Still, given how specialized this business is, the high barriers to entry, and the lead we've built over the years, I just want to understand what's behind this stretch of nearly eight years where return on capital sits below your cost of capital.
I think we should clarify what ROCE metric we're actually looking at. In the mature markets — India, where we've operated for over 2, 3 decades — our ROCEs sit in the 20% range. We're adding markets that are 20 to 30x larger than our Indian market. And over the last many years, we've been putting in proportionate or disproportionately higher amounts of money to penetrate these markets. So ROCEs will stay subdued. And as the business grows, the ROCEs will begin to look healthy.
So what gives us confidence that this expansion we're pursuing outside our home market will actually deliver the results we're after, given that we've been investing for a reasonably long stretch of time now? I just want to get a sense of what underpins our confidence to keep expanding.
The thing to keep in mind is that this isn't a case of us putting money into just one area. Our investment activity has been ongoing. Our aim is to rank among the top Fragrance and Flavour companies globally. We began in the India market, which represents 5% or less of the worldwide market, and as we expand we want to capture the remaining 95% of that global market. So investments will keep happening. We made a very big jump in 2024, and the reason was the landscape of other competitive opportunities — the bigger companies had mergers, and that created a good opening for midsized companies. So as the industry presented us with opportunity, we took big jumps in U.S.A. and Europe with respect to our investment portfolio. And unfortunately, we had a fire incident two years ago. So we have a bit of negative CapEx, or double CapEx, in the domestic market as we recover from that incident. So I would say this is not the healthiest situation. This is not the ROCE you see when everything is going well. This is the ROCE with our expansion continuing despite some setbacks in our domestic business. And we expect that by next year, the domestic business, capital employed and new factory will start to push our ROCEs back to normal levels.
That said, if you'd like a quick way to size it up, we spend roughly INR 80 crores across our CDCs, and those aren't producing any meaningful revenue at this point. So if you take that INR 80 crores out and put it back into profitability, you'll be able to see what the underlying ROCEs look like for our mature business.
Understood. And just so I’m clear, when do you expect revenue will be sufficient to make up for those losses?
My view is that losses aren’t what we’re posting. I’d frame it as us putting money into future growth, funded by profits from the business we already run, directed toward new markets. A solid 3 to 4 years will pass before those markets reach breakeven on a standalone basis, and after that a further 3 to 4 years of continued growth will be needed before this investment produces meaningful returns. This is a long-term effort. Seven, eight years will pass before those businesses are delivering a solid return on investment.
Okay, so I want to make sure I've got this right. That EBITDA margin of roughly 12% to 13% that we've posted over the past couple of quarters — is that a number we can think of as sustainable, one that will rise from here? Or is there something a bit exceptional in there, say from carrying some low-cost inventory or anything along those lines?
So that 13% really sits toward the low end of what we consider a sustainable EBITDA level, which is what we're delivering right now. It's on the softer side. We do expect that to get better.
Okay, thank you. And one final item — looking ahead across the coming 2 to 3 years, can you offer us any sort of guidance on both revenue and margins?
We're therefore focused on keeping revenue growth above 12%. That will hinge on inflation and volume, but on a continuing basis we're expecting 12% to 13% growth on the top line. On top of that, we're aiming somewhat higher for EBITDA growth. So with 12% revenue growth, we'd expect 14%; that means 13% to 14% EBITDA growth year-on-year over the next...
And considering that the Indian market, I assume, is expanding at a low double-digit pace, while our offshore base is very small, shouldn't our growth rate be materially above 12%, given all the investments we've made?
Yeah, I'd expect it to ramp up. Some of those older businesses have bases that aren't really expanding quickly. So in effect, that 12% works out to 25% on the new business, given the large block of existing business that's at a steady state — mature, penetrated markets.
You're making the point that ideally the growth would be faster — is that what you're saying?
There are two pieces to this growth. It isn't just new products that are driving us. Our existing products, which have been on the market for many decades, are now rising at 5%, 6%. That's as fast as they go. Their market penetration is complete. They are still growing, but 20% growth is not in the cards for them. So the growth in the business stems from new products and new categories, which are expanding at 25%. That brings the composite to 12%.
The next question is from Pranav Tendolkar of Rare Enterprises.
Sir, how are things going with the expansion in Germany, the U.K., and the U.S.? Are there any new clients added, and so on, that you could shed some light on?
So essentially, in Germany and the U.K., we've brought on new clients. In those markets, we don't have any Fragrance clients already in place. It's all new business, driven by new products and new clients.
Okay, sir. Earlier you said Germany is going to break even this year and grow at a faster pace. So are there similar milestones you can share for the other geographies where we've put in investment?
We haven't said it would reach break-even. Essentially, it's beginning to bring in revenue. So at this point we're scaling those revenues up. We're not — so the past year and a half was mainly about building the team, getting the system in place, getting product out to the client, making that first, first move. We're now seeing revenue start to come in across all three of these markets. They'll become meaningful as we go. Ramping up to significant numbers, relative to the company as a whole, will take another 12 months to 18 months. 100%, but the base is very small. So we see it ramping up quickly, but it will be meaningful. For these revenues to matter within the company's overall revenues, it will take at least 12 to 18 months.
Our following question is from Jatin Chawla, who is calling in from RTL Investments.
You said you view that 13% margin as the bottom of the range, I believe. And in the past, I think you've said 15% is more the baseline you'd want. So what timeframe do you see for reaching that 15% margin? Would that come in FY '28, or later than that?
From our perspective, what we track regarding inflation is somewhat uncertain. Over the last six months, base inflation has been very high given all the disturbances. Assuming we're at a steady state, in 12 months' time we ought to hit the 15% EBITDA. Should further inflation continue, it probably takes two years. But somewhere between 12 to 18 months, we'll see operating leverage kick in and our target of 15% EBITDA plus will come into the picture.
Understood. On Flavours, I believe there was a sizable order in 1Q. But that 2Q Flavours run rate of INR 72 crores in revenue — do you view that as a sustainable run rate?
Right. I'd say the Q2 run rate is somewhat below the typical run rate. Q1 came in considerably higher. So the average, I think, lands somewhere between them — around 72 or 73, which is the.
For Q2, that's 72. And for H1, it's 180.
I'd say around 90, 85 crores — INR 90 crores each quarter is the right run rate. Q2 came in under that run rate. Q1 was over the...
Understood. And looking at the first half, you've already posted 13%, 14% growth. We're generally seeing some recovery in consumption in India, so growth ought to accelerate. And given all the investments you've made in CDC, your overseas business should also grow at a faster clip. So why are we looking at only a 12%, 13% growth going forward rather than 15% kind of growth?
Looking at it on a midterm basis, I think we've had roughly 15% year-on-year growth for several years, and then macro events have come along — a pandemic or something similar — where growth stays flat for six months or nine months. So we don't want to overestimate the CAGR. I'd say 12%, 13% growth year-on-year. There may be years when we hit 15%, 16%, perhaps an even higher rate. But on average, year-on-year, 12% to 13% is what we see from here. Compared with some global peers, the very large global companies, they're achieving 2% to 3% average growth in these markets. So with a global average of 3% to 4%, if we're delivering 13%, 14%, we'll be at a good clip. And we're not talking about 12%, 13% on a sort of like-for-like basis. So we expect 12%, 13% growth even in Euro terms and in Euro like-for-like currency. So double-digit growth in like-for-like currency, if we get the benefit of currency exchange — and that isn't counted in the 12% to 13% growth.
Understood.
The other side of that is the inflation assumption. I think anyone's assumption from last year to this year is that inflation has come in much higher than any predicted figure. So we see a net volume impact from that. If inflation stays sort of neutral or within the normal range, growth rates can recover beyond the 12%-13%.
Understood, understood. One final question from me. Looking at your other expenses, they've been roughly steady around that INR 95 crore mark across the last three quarters. Interest cost and depreciation, though, continue to climb. And my assumption is that as new CapEx comes on stream, those would likely rise somewhat more. So what would you view as a sustainable run rate for interest and depreciation costs?
If you look at interest, this quarter it's nearly INR 17.5 crores, which appears to be roughly at a peak. But interest rates are rising. And although we will bring down the debt — which we're aiming to reduce — interest for the second half will stay more or less in the INR 16 crores to INR 17 crores per quarter range. On depreciation, once capitalization happens for the new facility, it will rise a bit. So we expect a rough depreciation run rate, on an annualized depreciation and amortization basis, of about INR 145 crores to INR 150 crores.
I’d like to add one more point: for certain acquisitions we’ve completed in Europe, the amortization will begin to decline at some stage within the next 2 to 3 years.
Apologies for cutting in, but your audio isn’t coming through for us.
Do you have any kind of indicative timeline on that?
A 10-year amortization period. So the first acquisition, in 2018, will begin to decrease from 2028 onward.
The operator has asked that we move to the next question, which will be coming from Tanish Jhaveri at FYERS Asset Management Company.
Yeah, I'd like to ask about the inventory build. When do we see that unwind happen and get back to our better working capital cycle? That's my first question.
During the next six months, we've been gradually getting this process underway. In October already, we brought some inventory down. Over the coming six months, we'll keep lowering our inventory intensity. So in total, we don't anticipate a dramatic drop in inventory. But as sales ramp up, we'll be handling higher sales with lower inventories.
Sure. And when should we expect the insurance claim to be closed? I think there's still some amount pending, right?
Yeah, by March 2 of this financial year.
Okay, and my final question is about our liabilities. The bulk of it is shifting into overdraft or short-term liabilities. Is there a way to reduce that, say by structuring it as a 3- to five-year loan so rollover dependence goes down? Or is all of this intended for working capital?
The bulk of it goes toward working capital, so it really hinges on what the uses are.
Our following question is from Bharat Sheth at Quest Investment Managers Private Limited.
A lot of what I wanted to ask has already been covered, though I'd still like to get a clearer picture — specifically on the Flavour side — of the kind of numbers we're talking about. So there will be substantial growth this year. How do we expect that momentum to hold up? And where might one look for a potential Flavour business?
I think with Flavour, obviously, growth above 40% is pretty unusual. What we consider the underlying growth is a sustainable 20% quarter-on-quarter. We saw extra sales — especially in exports, given freight issues and disruptions in the Middle East and other markets. That produced a big chunk of additional revenue in the first quarter, and we view it more as a one-off transaction, with customers raising inventory levels because of longer lead times, logistics uncertainty, et cetera. So we don't think — it isn't consumption. It's additional sales. So the pipeline of inventory between us and the clients' usage has gone up. Beyond that, I think 20%-plus is sustainable growth for Flavour. As we saw after the pandemic, there's been a particularly huge shift toward packaged food, and industry growth in processed food has been substantial, on top of the 7%, 8% volume consumption growth as the population grows. We've seen extra Flavour usage because of packaged food or Flavoured products. Take simple products like dairy — previously, and even now, I think roughly 3% of dairy is Flavoured or processed in the totality.
However, with the shift increasingly toward packaged and bottled milk, along with flavored milk and flavored products, that proportion is climbing. In India, food processing and factory output are steadily gaining ground in every facet of the food sector and what people eat. Numerous small bakeries around the nation can now reach far more customers via the D2C channel. As a result, some are broadening their geographic footprint by leveraging the D2C approach. Meanwhile, a lot of the smaller retail shops have shut their doors. So overall food intake—and the share of processed food within that total—is expanding quickly. Our market share is fairly modest. Therefore, we anticipate sustaining growth of 20% or roughly that level year over year.
So in '27, with that larger base, we might see some decline in '28, and after that we'll grow 20% off whatever base we've built up — that's because people have accumulated our inventory. So that's the whole picture..
Yes. I'd use 40% as the baseline. This year I'd also include the 20%—if you look at roughly INR 20 crores of business in the first quarter, we can call that a one-off in terms of clients purchasing inventory and then the consumption that follows—and we end up with something like 127% for the first half on a sustainable basis. And we'll keep building it progressively. We've actually grown our development strength within Flavours to almost double what it was two years ago. So things are—we have the capability, the capacity, and the development team ready to raise the rate of increase.
All right, great. And I've got one more question for Jagdish. So, Jagdish, what's the CapEx still pending — I mean, as of today, in cash flow terms, taking both factories into account?
This will carry into the following year as well. So, speaking of this year, what's left of CapEx for this year — for financial year '27 — falls in the range of INR 30 crores to INR 35 crores. As we shift into '27 '28, a portion of CapEx is also moving into the next year.
What would that amount to for '28? Could you provide a bit more context on that?
Yes — for '27 and '28, somewhere between INR 75 crores and INR 80 crores.
The total figure, and this covers all capital expenditures...
We're looking at INR 30 crores this year, and then INR 50 crores the following year.
And apart from that, what would the sustenance CapEx be?
Which capital expenditure are you referring to? Do you mean operational CapEx?
Yeah, maintenance and...
Which comes to roughly INR 50 crores.
Our following question is from Raghuram Kuchi, who is calling in from Bestpals Research & Advisory LLP.
Sir, I just wanted to get a sense of your D2C investments, since Europe and the U.S. are mature markets. What gives you confidence, or what is our right to win there? I just wanted to understand that aspect, because both markets are mature — how are we able to get a foot in? And what is the reason we're getting orders in these markets? And who are we supplying to? Will we be serving large customers, or the SME or mid segment? I just wanted to get an understanding of the market.
There are two forces at work around the world in the developed markets of Europe and America. The first is a worldwide pattern: with direct-to-consumer and Internet-based marketing emerging, plenty of small brands can now reach a larger market. As a result, smaller clients' share of the total Fragrance market is in fact growing. That gives smaller players such as us an opening in America and Europe. The second development in the industry over the last — it's an ongoing trend, though over the last 10 years it has somewhat hit saturation — is a huge wave of consolidation. So at present, three or four companies, let's say five companies, are multibillion-dollar companies. And then there are virtually no companies between our size and those multibillion-dollar companies, since all of them have been acquired, merged, or consolidated in Europe and America. So a wide space, an open space, exists for midsized and smaller company clients, which we intend to take on. At the same time, we are one of the only midsized and smaller companies holding global technology and First-to-the-World innovation platforms.
Basically, we're going up against midsized firms throughout Europe and America, using capabilities that the big global players can deliver. What we bring together is a global company's technological edge with the nimbleness and the cost structure of a small company. That's the proposition we offer. It lines up precisely with where the market is expanding and with what customers require.
So what would the market size be if we just need to get — because you mentioned the markets are 20x that of India. But I'm assuming the market you're referring to here is different, it's the same thing, 20x of the India business.
In these markets, the fragrance category is actually 35x the size of India. So in total, across Europe and America, we’re looking at a $20 billion to $24 billion fragrance market. If we strip out some of the ingredients and the sale of those, we’re still looking at a $10 billion addressable market in the U.S.A. and Europe.
So if we leave out what the top 4 players provide, then aside from that, you're saying a $10 billion market is out there...
All the formulations we sell across those two regions bring in roughly $10 billion in revenue.
Could you expand a bit more on the Southeast — how are your investments taking shape there, and how is the market growing for...
Looking at Southeast Asia, previously, particularly through the pandemic period, supply chain problems arose for us since we were attempting to source out of India, and their shipping lines and logistics weren't efficient. Since last year we've been running our Jakarta factory, and it's performing extremely well. It has been fully operational since September last year. We're now positioned to offer clients short lead times, and growth is coming in as a result, with midsize and larger clients now handing us business opportunities with far greater confidence than before. So for Southeast Asia as a business, we're seeing promising green shoots. It keeps expanding, and we're well placed to capture that growth.
Is that 12% growth rate something we can keep up across a three-to-five-year span? In other words, which investments have we already made that will carry us through the coming few years and support 12% growth on the top line?
Yeah, the percentage growth may appear large, but the market itself is far larger than India's. The absolute numbers we're adding aren't all that significant. We're talking about an increase of 2 million to 3 million each year. So we're quite confident that we can achieve that — or even surpass it.
Our next question is from Praveen Agarwal, who is an individual investor.
I’ve only got a couple of questions. The first one is about this FTA — so once the European FTA comes into effect, does it help us in any way or form?
My sense is that this probably won't matter much in our sector. In any case, duties on finished goods are already low in both directions. So it isn't material. No opportunity will come out of the FTA, and none will be lost either.
Second, sir, looking at your stand-alone figures — which account for roughly 50% of the business — some of the margins in that stand-alone operation, which I assume is mostly the India business, are considerably lower. If I check the track record, historically, at least on a reported basis, it was about 14%, 15% per annum. And over the last two years, even including this year, it has dropped to 2%, 3% in the stand-alone numbers. So I'm just trying to understand what's going on here.
So look, because of what happened with the fire, every one of our operations has shifted over to the subsidiary companies at KFPL and KFVL — those are the factories we're running today. That means the stand-alone figures don't really show what the business is actually doing. So we have to bring the operating costs and the margins from those subsidiaries together with the standalone.
That brings us to the final question.
My view is that once the business returns to direct operations next year, those figures will come back.
Got it. Sir, one more question. Sir, you have the smaller players — and I realize this isn't an apples-to-apples comparison in India, like Privi and then another very tiny company called <<inaudible>>. Their margins and growth are significantly higher. So what are they doing? How have they managed to — and we are the market leaders in this space. So what are they doing, where, how are they able to grow faster than us, basically?
I believe these are really two distinct kinds of companies we're discussing, and one of them is the one you brought up, Privi. At this point Privi is essentially at a stage of full investment and full growth. India is where its main business sits. It's a specialty chemical operation built around exports. Since the ingredient business has enjoyed quite strong tailwinds — because of the devaluation of the China currency relative to the India currency, Chinese producers have become less competitive, or to put it the other way, Indian producers have become more competitive — we've watched that dynamic unfold. Privi particularly has performed extremely well over the last 2, 3 years. So that's the nature of the ingredient business: inflation and the shortages have benefited them. You mentioned a second company, and on that one I think I don't have much knowledge.
Ladies and gentlemen, since participants have no more questions, I'll now return the conference to management for closing remarks. Sir, the floor is yours.
Thanks. I hope our responses have addressed your questions in a satisfactory way. If anything still needs clarifying, or if you'd like additional information about the company, you're welcome to reach out to our team or to CDR India. Thanks again for being with us on this call.
Thanks.
Thank you, members of the management team. That brings this conference to a close on behalf of SH Kelkar & Company Limited. Thanks to all of you for being with us, and you can go ahead and disconnect your lines at this point. Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete S H Kelkar and Company Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to S H Kelkar and Company Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.